Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • AJNR Case Collection
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • Special Collections
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
    • 2024 AJNR Journal Awards
    • Most Impactful AJNR Articles
  • Multimedia
    • AJNR Podcast
    • AJNR Scantastics
    • Video Articles
  • For Authors
    • Submit a Manuscript
    • Author Policies
    • Fast publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Manuscript Submission Guidelines
    • Imaging Protocol Submission
    • Submit a Case for the Case Collection
  • About Us
    • About AJNR
    • Editorial Board
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Other Publications
    • ajnr

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • AJNR Case Collection
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • Special Collections
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
    • 2024 AJNR Journal Awards
    • Most Impactful AJNR Articles
  • Multimedia
    • AJNR Podcast
    • AJNR Scantastics
    • Video Articles
  • For Authors
    • Submit a Manuscript
    • Author Policies
    • Fast publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Manuscript Submission Guidelines
    • Imaging Protocol Submission
    • Submit a Case for the Case Collection
  • About Us
    • About AJNR
    • Editorial Board
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

Welcome to the new AJNR, Updated Hall of Fame, and more. Read the full announcements.


AJNR is seeking candidates for the position of Associate Section Editor, AJNR Case Collection. Read the full announcement.

 

Research ArticleBRAIN

MR Imaging Correlates of Survival in Patients with High-Grade Gliomas

Whitney B. Pope, James Sayre, Alla Perlina, J. Pablo Villablanca, Paul S. Mischel and Timothy F. Cloughesy
American Journal of Neuroradiology November 2005, 26 (10) 2466-2474;
Whitney B. Pope
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Sayre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alla Perlina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Pablo Villablanca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul S. Mischel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy F. Cloughesy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 1.

    MR images of patients with GBM.

    A, Axial postcontrast T1-weighted images. There is an enhancing tumor with central, irregular hypoenhancement consistent with necrosis.

    B, Axial T2-weighted images of the same patient shown in panel A. High T2-weighted signal intensity surrounds the tumor, with signal intensity approaching that of CSF as seen in the lateral ventricles. The T2-weighted signal intensity change respects the cortical ribbon. The appearance is indicative of vasogenic edema (grade 2, extending more than 1 cm from the tumor, per definitions in Table 1).

    C, Axial postcontrast T1-weighted images of another GBM patient. As in the first case there is an enhancing tumor with irregular central hypoenhancement indicating necrosis.

    D, Axial T2-weighted images of the same patient shown in panel C. Adjacent to the enhancing portion of the tumor, there is increased T2-weighted signal intensity, which is significantly lower than that of CSF, which extends into the cortex and does not respect the cortical ribbon. The gray-white distinction is obscured. The region corresponds to areas of mildly low T1-weighted signal intensity. This appearance reflects the presence of nonenhancing tumor (nCET). There is also a sliver of higher T2-weighted signal intensity change at the medial margin of the tumor, which indicates a small amount of edema.

  • Fig 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 2.

    Survival curves for glioblastoma. Favorable (n = 16) is tumors with nCET and without edema, satellites, and multifocal disease. Unfavorable (n = 17) is edema, and either satellites or multifocal disease, without nCET (n = 110 for all GBM patients).

  • Fig 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 3.

    Recursive partitioning analysis. All 15 imaging features as described in the Methods section were entered into the recursive partitioning algorithm. The 95% confidence intervals are shown in parentheses.

Tables

  • Figures
    • View popup
    TABLE 1:

    Imaging definitions

    VariableScoreScore Description
    Necrosis0 no, 1 yesNecrosis is defined as a region within the tumor that does not enhance or shows markedly diminished enhancement, is high on T2W and proton density images, is low on T1W images, and has an irregular border
    Enhancement0 no, 1 yesContrast enhancement is defined as having all or portions of the tumor that demonstrate significantly higher signal on the postcontrast T1W images compared to precontrast T1W images
    Enhancing rim0 none, 1 thin, 2 thick, N/AIf most of the enhancing rim is thin, regular, and has homogenous enhancement, the tumor receives a score of 1. If most of the rim demonstrates nodular and/or thick enhancement, the score is 2. If there is only solid enhancement and no rim, the score is 0. The scoring is not applicable if there is no contrast enhancement
    Enhancing margin0 well defined, 1 poorly defined, N/AIf most of the outside margin of the enhancement is well defined, the tumor is scored 1 The scoring is not applicable if there is no contrast enhancement
    NEM (grade III)0 smooth, 1 irregularIf most of the outside nonenhancing margin of the tumor is well defined and smooth (geographic), the tumor is scored 0. If the margin is ill defined, the tumor is scored 1
    Solid enhancement0 none, 1 part, 2 all, N/AIf the enhancing portion of the tumor enhances solidly, without cystic or necrotic components, the tumor is scored 2. If there are both regions of solid enhancement as well as necrosis or central irregular nonenhancement or cyst formation, the tumor is scored 1. If the tumor demonstrates only peripheral or ring enhancement without significant portions, the tumor is scored 0. If there is no enhancement, this variable is not applicable
    nCET0 no, 1 yesNonenhancing tumor is defined as regions of T2W hyperintensity (less than the intensity of cerebrospinal fluid, with corresponding T1W hypointensity) that are associated with mass effect and architectural distortion, including blurring of the gray-white interface
    Edema0 none, 1 mild, 2 moderate/severeIf no convincing edema, as demonstrated by regions of very bright T2W signal, then a score of 0 is given. If there is clearly visible, bright T2W signal not associated with mass effect and architectural distortion (see nonenhancing tumor) and not extending more than 1 cm beyond the tumor margin, the score is 1. If there is more extensive, very bright T2W signal intensity, often following white-matter tracts and extending significantly beyond (>1 cm) the margins of the tumor, the edema is scored a 2
    Cyst(s)0 no, 1 yesCysts are well defined, rounded, often eccentric regions of very bright T2W signal and low T1W signal essentially matching CSF signal intensity, with very thin, regular, smooth, nonenhancing or regularly enhancing walls, possibly with thin, regular, internal septations
    Multifocal0 no, 1 yesMultifocal is defined as having at least one region of tumor, either enhancing or nonenhancing, which is not contiguous with the dominant lesion and is outside the region of signal abnormality (edema) surrounding the dominant mass
    Satellites0 no, 1 yesA satellite lesion is within the region of signal abnormality surrounding the dominant lesion but not contiguous in any part with the major tumor mass
    Extent of resection<20%, 20%–89%, 90%–99%, 100%The first postoperative scan (contrast-enhanced MR imaging) was assessed for tumor residual. Presence of both enhancing and nonenhancing tumor was determined. Scans were scored 100% resection if no tumor residual was visible. Trace tumor residual <10% of the total corresponded to the 90%–99% category. If the tumor was debulked, but substantial tumor remained, a score of 20%–89% was used. If the tumor was biopsied only, then 0%–19% was used.
    TCM0 no, 1 yes
    ECM0 no, 1 yes, N/A
    LocationFrontal, parietal, temporal, occipital, corpus callosum, thalamus
    SizeUnidimensional, largest diameter in millimeters
    SideLeft, right
    • Note.—NEM indicates nonenhancing margin; nCET, noncontrast-enhancing tumor; TCM, tumor crosses midline; ECM, edema crosses midline.

    • View popup
    TABLE 2:

    Demographics

    AttributeGrade III GliomasGlioblastoma
    MeanSD95% CIMeanSD95% CI
    Age40.414.136.4–45.254.914.352.0–57.8
    KPS86.912.882.9–90.984.214.181.4–87
    Survival (days)20102321560–246074860.6630–867
    SexFemale, 52.4%Female, 34.5%
    Male, 47.6%Male, 65.5%
    OligodendrogliomaNoneMinorMajorNoneMinorMajor
    Component (%)38.128.633.385.57.27.3
    Resection (%)10090–9920–890–1910090–9920–890–19
    16.626.231.026.233.723.526.516.3
    • Note.—KPS indicates Karnofsky performance status.

    • View popup
    TABLE 3:

    Hazard ratios and confidence intervals by attribute

    AttributeGrade III GliomasGlioblastomas
    HR95% CIP ValueHR95% CIP Value
    Clinical
        Age3.741.09–12.9.0362.291.35–3.86.002
        KPS0.960.93–0.99.0060.980.96–0.99.005
        Oligodendroglioma component1.060.55–2.07.8540.580.34–0.99.047
        Resection1.220.67–2.23.5171.080.85–1.37.530
    Imaging
        Enhancing rim1.680.34–8.37.5191.160.73–1.84.522
        SE0.790.38–1.61.5081.040.66–1.63.863
        CE3.300.71–15.3.1271.530.21–11.10.68
        ECM2.450.76–7.87.1341.330.81–2.21.264
        TCM2.450.76–7.87.1341.310.72–2.36.374
        Location0.970.63–1.52.9141.040.88–1.23.639
        Multifocal18.73.06–115.0024.342.11–8.92.001
        Necrosis4.431.35–14.6.0141.240.30–5.09.764
        nCET0.050.01–0.55.0140.550.33–0.92.023
        EM0.320.07–1.35.1210.640.37–1.12.120
        NEM2.950.85–10.3.089
        Satellites5.181.11–24.1.0361.741.03–2.93.038
        Side0.800.17–3.79.7821.290.79–2.07.300
        Size1.160.90–1.50.2351.050.94–1.17.393
        Cyst0.030.00–20.8.3020.920.46–1.80.799
        Edema1.990.79–3.99.1581.621.18–2.22.003
    • Note.—HR indicates hazard ratio (of dying); KPS, Karnofsky performance status; SE, solid enhancement; CE, contrast enhancement; ECM, edema crosses midline; TCM, tumor crosses midline; nCET, noncontrast-enhancing tumor; EM, enhancing margin; NEM, nonenhancing margin.

    • View popup
    TABLE 4:

    Correlations for glioblastoma clinical and imaging features

    KPSAgeNecrosisnCETEdema
    KPS−0.290−0.1560.100−0.128
        P.002.103.301.184
    Age−0.2900.194−0.3740.300
        P.002.042.001.001
    nCET0.100−0.374−0.076−0.357
        P.301<.001.429<.001
    Edema−0.1280.3000.159−0.357
        P.184.001.098<.001
    Multifocality−0.1780.1490.0690.174.165
        P.063.119.474.0690.084
    Satellites−0.0640.1050.1310.0250.122
        P.510.275.174.792.204
    • Note.—KPS indicates Karnofsky performance status; nCET, noncontrast-enhancing tumor. Correlations with P values <.05 are set in boldface type.

PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 26 (10)
American Journal of Neuroradiology
Vol. 26, Issue 10
1 Nov 2005
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MR Imaging Correlates of Survival in Patients with High-Grade Gliomas
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
Whitney B. Pope, James Sayre, Alla Perlina, J. Pablo Villablanca, Paul S. Mischel, Timothy F. Cloughesy
MR Imaging Correlates of Survival in Patients with High-Grade Gliomas
American Journal of Neuroradiology Nov 2005, 26 (10) 2466-2474;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
MR Imaging Correlates of Survival in Patients with High-Grade Gliomas
Whitney B. Pope, James Sayre, Alla Perlina, J. Pablo Villablanca, Paul S. Mischel, Timothy F. Cloughesy
American Journal of Neuroradiology Nov 2005, 26 (10) 2466-2474;
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • References
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Association of Graph-based Spatial Features with Overall Survival Status of Glioblastoma Patients
  • MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features
  • Assessment of Prognostic Value of Cystic Features in Glioblastoma Relative to Sex and Treatment with Standard-of-Care
  • Deep Transfer Learning and Radiomics Feature Prediction of Survival of Patients with High-Grade Gliomas
  • Prognostic value of magnetic resonance imaging features in low-grade gliomas
  • Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research
  • Predicting cancer outcomes from histology and genomics using convolutional networks
  • Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas
  • Predicting cancer outcomes from histology and genomics using convolutional networks
  • MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication
  • Radiomics in Brain Tumor: Image Assessment, Quantitative Feature Descriptors, and Machine-Learning Approaches
  • T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
  • The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated MGMT Promoter
  • Early-Stage Glioblastomas: MR Imaging-Based Classification and Imaging Evidence of Progressive Growth
  • Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma
  • The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival
  • Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation
  • Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI
  • MRI Grading versus Histology: Predicting Survival of World Health Organization Grade II-IV Astrocytomas
  • Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma
  • Extent of Resection of Glioblastoma Revisited: Personalized Survival Modeling Facilitates More Accurate Survival Prediction and Supports a Maximum-Safe-Resection Approach to Surgery
  • Arterial Spin-Labeling Assessment of Normalized Vascular Intratumoral Signal Intensity as a Predictor of Histologic Grade of Astrocytic Neoplasms
  • Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma
  • Survival Analysis of Patients with High-Grade Gliomas Based on Data Mining of Imaging Variables
  • Conventional MRI evaluation of gliomas
  • Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin
  • Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours
  • Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
  • Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2
  • MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Optimal MRI Sequence for Identifying Occlusion Location in Acute Stroke: Which Value of Time-Resolved Contrast-Enhanced MRA?
  • SWI or T2*: Which MRI Sequence to Use in the Detection of Cerebral Microbleeds? The Karolinska Imaging Dementia Study
  • Progression of Microstructural Damage in Spinocerebellar Ataxia Type 2: A Longitudinal DTI Study
Show more Brain

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editors Choice
  • Fellow Journal Club
  • Letters to the Editor

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

Special Collections

  • Special Collections

Resources

  • News and Updates
  • Turn around Times
  • Submit a Manuscript
  • Author Policies
  • Manuscript Submission Guidelines
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Submit a Case
  • Become a Reviewer/Academy of Reviewers
  • Get Peer Review Credit from Publons

Multimedia

  • AJNR Podcast
  • AJNR SCANtastic
  • Video Articles

About Us

  • About AJNR
  • Editorial Board
  • Not an AJNR Subscriber? Join Now
  • Alerts
  • Feedback
  • Advertise with us
  • Librarian Resources
  • Permissions
  • Terms and Conditions

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire